Cited 14 time in
Recent challenges and advances in genetically-engineered cell therapy
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Yong, Seok-Beom | - |
| dc.contributor.author | Chung, Jee Young | - |
| dc.contributor.author | Song, Yoonsung | - |
| dc.contributor.author | Kim, Yong-Hee | - |
| dc.date.accessioned | 2021-07-30T05:17:12Z | - |
| dc.date.available | 2021-07-30T05:17:12Z | - |
| dc.date.issued | 2017-12 | - |
| dc.identifier.issn | 2093-5552 | - |
| dc.identifier.issn | 2093-6214 | - |
| dc.identifier.uri | https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/3954 | - |
| dc.description.abstract | Cells naturally sense and actively response to their environment. Cell-therapy has long been studied and shown therapeutic effects in various diseases. However, several hurdles should be overcome to improve cell-based therapy. Gene delivery-mediated cellular modification has shown improvement of cell function by obstacle gene silencing and therapeutic gene expression. Especially, CRISPR/Cas9-mediated genome editing is a very promising method for gene modification. In this review, we describe the recent advances in genetic modification for cell therapy. Stem cells are still promising source of cell therapy due to their self-renewal character and differentiation potential. Immune cells regulate the inflammatory response and immunization, which inspired various cell therapy using immune-regulatory cells. Conclusively, we emphasize the need to develop gene-modification-based cell therapy as potent future treatment. | - |
| dc.format.extent | 10 | - |
| dc.language | 영어 | - |
| dc.language.iso | ENG | - |
| dc.publisher | 한국약제학회 | - |
| dc.title | Recent challenges and advances in genetically-engineered cell therapy | - |
| dc.type | Article | - |
| dc.publisher.location | 대한민국 | - |
| dc.identifier.doi | 10.1007/s40005-017-0381-1 | - |
| dc.identifier.scopusid | 2-s2.0-85042428848 | - |
| dc.identifier.bibliographicCitation | Journal of Pharmaceutical Investigation, v.48, no.2, pp 199 - 208 | - |
| dc.citation.title | Journal of Pharmaceutical Investigation | - |
| dc.citation.volume | 48 | - |
| dc.citation.number | 2 | - |
| dc.citation.startPage | 199 | - |
| dc.citation.endPage | 208 | - |
| dc.type.docType | Review | - |
| dc.identifier.kciid | ART002325058 | - |
| dc.description.isOpenAccess | N | - |
| dc.description.journalRegisteredClass | scopus | - |
| dc.description.journalRegisteredClass | kci | - |
| dc.subject.keywordPlus | chemokine receptor CCR2 | - |
| dc.subject.keywordPlus | chimeric antigen receptor | - |
| dc.subject.keywordPlus | interleukin 12 | - |
| dc.subject.keywordPlus | interleukin 18 | - |
| dc.subject.keywordPlus | transforming growth factor beta | - |
| dc.subject.keywordPlus | atherosclerosis | - |
| dc.subject.keywordPlus | bone marrow derived mesenchymal stem cell | - |
| dc.subject.keywordPlus | cancer immunization | - |
| dc.subject.keywordPlus | cell differentiation | - |
| dc.subject.keywordPlus | cell function | - |
| dc.subject.keywordPlus | cell proliferation | - |
| dc.subject.keywordPlus | cell therapy | - |
| dc.subject.keywordPlus | cell transplantation | - |
| dc.subject.keywordPlus | CRISPR-CAS9 system | - |
| dc.subject.keywordPlus | gene | - |
| dc.subject.keywordPlus | gene expression | - |
| dc.subject.keywordPlus | gene mutation | - |
| dc.subject.keywordPlus | gene silencing | - |
| dc.subject.keywordPlus | gene therapy | - |
| dc.subject.keywordPlus | genetic engineering | - |
| dc.subject.keywordPlus | glucose metabolism | - |
| dc.subject.keywordPlus | heart infarction | - |
| dc.subject.keywordPlus | hematopoietic stem cell | - |
| dc.subject.keywordPlus | immune response | - |
| dc.subject.keywordPlus | immunization | - |
| dc.subject.keywordPlus | immunosuppressive treatment | - |
| dc.subject.keywordPlus | inflammation | - |
| dc.subject.keywordPlus | mesenchymal stem cell | - |
| dc.subject.keywordPlus | phase 2 clinical trial (topic) | - |
| dc.subject.keywordPlus | priority journal | - |
| dc.subject.keywordPlus | protein expression | - |
| dc.subject.keywordPlus | Review | - |
| dc.subject.keywordPlus | sosc1 gene | - |
| dc.subject.keywordPlus | thalassemia | - |
| dc.subject.keywordPlus | was gene | - |
| dc.subject.keywordPlus | Wiskott Aldrich syndrome | - |
| dc.subject.keywordAuthor | Cell therapy | - |
| dc.subject.keywordAuthor | Gene engineering | - |
| dc.subject.keywordAuthor | Gene-modified cell therapy | - |
| dc.subject.keywordAuthor | Immune cell therapy | - |
| dc.subject.keywordAuthor | Stem cell therapy | - |
| dc.identifier.url | https://link.springer.com/article/10.1007/s40005-017-0381-1 | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
222, Wangsimni-ro, Seongdong-gu, Seoul, 04763, Korea+82-2-2220-1366
COPYRIGHT © 2024 HANYANG UNIVERSITY.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.
